EA-1356 (also written as EA 1356) is a G-series organophosphate nerve agent chemically known as 2-methylcyclohexyl methylphosphonofluoridate, or methyl cyclosarin. Developed and tested at Edgewood Arsenal in Maryland, it is classified as a Schedule 1 substance under the Chemical Weapons Convention and works by inhibiting acetylcholinesterase. Its unusual resistance to enzymatic breakdown made it a subject of U.S. Army decontamination research for decades.
Most people have heard of sarin. Fewer know about cyclosarin. Almost nobody outside of defense research circles knows about EA-1356—and that obscurity is precisely what makes it so scientifically significant.
EA 1356 is a fluorinated organophosphate nerve agent that shares structural DNA with both sarin and cyclosarin, yet behaves differently enough to have posed a distinct challenge to military decontamination scientists. It was synthesized, tested, and largely shelved during the Cold War era of chemical weapons development at Edgewood Arsenal in Maryland. But the story didn’t end there. Decades later, U.S. Army researchers were still wrestling with how to neutralize it efficiently—a challenge that ultimately produced a patented enzymatic breakthrough in 2018.
This article covers everything known about EA-1356 in the open scientific and defense literature: its chemical identity, its origins, how it disrupts human physiology, why it resisted standard enzymatic decontamination, and what the U.S. Army’s patent-backed research means for chemical defense technology. For readers interested in how emerging science and technology intersect with national security, this is a case study unlike most others.
What Is EA-1356? A Precise Chemical Definition
EA-1356 is the Edgewood Arsenal designation for the compound formally named 2-methylcyclohexyl methylphosphonofluoridate. It is also referred to as methyl cyclosarin, a name that immediately signals its relationship to cyclosarin (GF), which is itself a close structural relative of sarin (GB).
Its key chemical identifiers are:
- CAS Number: 85473-32-1
- Molecular Formula: C₈H₁₆FO₂P
- Molar Mass: 194.186 g/mol
- Chemical Class: G-series organophosphonate nerve agent
The “G-series” label refers to a family of nerve agents—including sarin, tabun, cyclosarin, and soman—originally developed in Germany before and during World War II. EA 1356 fits within this family because of its organophosphate backbone and fluorine-based leaving group, both hallmarks of classic G-agents. The methylcyclohexyl ester group, however, gives EA-1356 a distinct steric profile compared to its better-known relatives, which has direct consequences for how enzymes interact with it.
For reference purposes, the compound’s entry in public chemical databases provides additional structural context alongside its toxicological classification.
Where Did EA-1356 Come From? The Edgewood Arsenal Testing History
Edgewood Arsenal, located in Maryland, served as the United States Army’s primary center for chemical and biological warfare research throughout most of the 20th century. During the Cold War, the facility synthesized, tested, and catalogued hundreds of chemical warfare agents and potential agents. The “EA” prefix in EA-1356 is simply the Edgewood Arsenal internal designation system—a numbering scheme applied to compounds under evaluation.
EA 1356 was developed as part of broader research into G-series nerve agents. The goal was to understand the relationship between molecular structure and toxicological potency, partly to develop more effective agents and partly to understand what adversaries might deploy. Cyclosarin itself was a compound of interest because it combined sarin-like acute toxicity with greater environmental persistence. Methyl cyclosarin, as a structural variant, offered researchers an opportunity to study how subtle changes to the cyclohexyl ring affected both lethality and degradation behavior.
The compound never saw battlefield deployment. Like many Edgewood Arsenal compounds, EA-1356 remained a research-stage agent—significant for what it revealed about organophosphate chemistry rather than for any direct military application. This pattern of research-without-deployment is common across the broader technology and innovation landscape: many breakthroughs emerge from work that never reaches production.
How EA-1356 Works: Acetylcholinesterase Inhibition Explained
EA-1356, like all G-series nerve agents, kills or incapacitates by inhibiting acetylcholinesterase (AChE)—an enzyme that terminates nerve signal transmission across synapses. Under normal physiological conditions, acetylcholine (ACh) is released at nerve endings, transmits a signal to the receiving cell, and is then rapidly broken down by AChE. This cycle allows discrete, controlled muscle contractions and glandular responses.
When EA 1356 enters the body—through inhalation, skin absorption, or ingestion—it binds covalently to the active site of AChE, blocking the enzyme from clearing acetylcholine. The result is continuous, uncontrolled nerve firing. The clinical consequences unfold in a predictable cascade:
- Muscarinic effects: Excessive secretions (saliva, tears, mucus), bronchoconstriction, urinary and fecal incontinence, bradycardia, and miosis (pupil constriction)
- Nicotinic effects: Muscle fasciculations, weakness, and eventually paralysis
- Central nervous system effects: Anxiety, seizures, loss of consciousness, and at high doses, respiratory failure
The lethality of organophosphate nerve agents comes primarily from respiratory failure—either from direct bronchoconstriction or from paralysis of the respiratory muscles. EA-1356’s methylcyclohexyl structure influences how rapidly it binds and whether the AChE-agent complex undergoes “aging” (a process that makes the inhibition irreversible), though specific aging rate data for EA 1356 is not widely available in open-source literature.
Why EA-1356 Resisted Enzymatic Decontamination
Standard chemical decontamination methods for G-agents include chemical hydrolysis using alkaline solutions and enzymatic neutralization using organophosphate-hydrolyzing enzymes. The most studied of these enzymes is organophosphorus acid anhydrolase (OPAA), a naturally occurring enzyme found in certain bacteria that can cleave the phosphorus-fluorine bond in G-agents.
OPAA works well against sarin. It works reasonably well against cyclosarin. But EA-1356 presented a substantially harder problem.
The methylcyclohexyl ester group in EA 1356 is bulkier and more sterically demanding than the groups found in sarin or conventional cyclosarin. This steric bulk interferes with how OPAA positions the substrate within its active site, reducing catalytic efficiency. In practical terms, naturally occurring OPAA degrades EA-1356 significantly more slowly than it degrades other G-agents of comparable toxicity—a gap that matters enormously when decontaminating personnel, equipment, or environments under operational conditions.
This resistance was not merely an academic concern. If a decontamination protocol effective against sarin failed against EA 1356, forces equipped for one threat would be inadequately protected against another. The practical gap between the agents’ decontamination profiles made EA-1356 a persistent research priority even as interest in the compound’s offensive potential waned.
The 2018 U.S. Army Patent: Engineering a Better Enzyme
The most significant recent development in EA-1356 research came in 2018, when the U.S. Army filed U.S. Patent 10,124,043, covering engineered mutations of the OPAA enzyme designed to improve catalytic efficiency against substrates including EA 1356.
The research, conducted under the auspices of the U.S. Army Chemical and Biological Center (now part of DEVCOM Chemical and Biological Center), applied directed evolution and rational protein engineering techniques to identify OPAA variants with altered active-site geometries. The objective was to create enzyme mutants that could better accommodate the sterically demanding methylcyclohexyl group of EA 1356 without sacrificing activity against other G-agents.
The results were significant: engineered OPAA mutants demonstrated approximately four times greater catalytic efficiency against EA-1356 compared to the wild-type enzyme. A fourfold efficiency improvement is a meaningful gain in decontamination science—it translates to faster neutralization, lower enzyme concentrations required, and potentially more effective field-deployable formulations.
You can review the patent details directly through the TechLink Center’s patent licensing database, which manages licensing for U.S. Army-developed technologies including this OPAA work. The 2018 patent represents one of the more concrete examples of how long-term, unglamorous defense research eventually yields transferable biotechnology.
This kind of incremental, methodical scientific progress—applying modern molecular biology to Cold War-era chemical problems—mirrors patterns visible across the technology sector more broadly, where decades-old problems often yield to new computational and experimental tools.
EA-1356 Under the Chemical Weapons Convention
EA 1356 is classified as a Schedule 1 substance under the Chemical Weapons Convention (CWC), the international treaty that prohibits the development, production, stockpiling, and use of chemical weapons. Schedule 1 is the most restrictive category, reserved for chemicals that have been developed as weapons or that pose a significant risk of being weaponized, and for which there are few or no legitimate non-weapons applications.
Schedule 1 classification means that:
- Production is prohibited except in small quantities for protective research, medical countermeasure development, or detection purposes
- Any quantities produced must be declared to the Organisation for the Prohibition of Chemical Weapons (OPCW)
- Transfer between states parties is heavily restricted
The CWC entered into force in 1997, and the OPCW maintains the Schedule 1 list. EA-1356’s inclusion reflects the international community’s recognition that even obscure, non-deployed organophosphate agents represent potential proliferation risks. The treaty’s verification mechanisms—including inspection regimes—are designed to ensure that Schedule 1 research remains within permitted bounds.
How EA-1356 Compares to Sarin and Cyclosarin
Understanding EA 1356 requires placing it in context alongside its better-known relatives.
Sarin (GB) is the most widely recognized G-agent. It is volatile, fast-acting, and degrades relatively quickly in the environment. Its isopropyl ester group makes it a good substrate for wild-type OPAA.
Cyclosarin (GF) replaces sarin’s isopropyl group with a cyclohexyl group. This makes cyclosarin more persistent in the environment and somewhat more resistant to enzymatic hydrolysis, though still addressable with standard OPAA-based decontaminants.
EA-1356 (methyl cyclosarin) goes one step further. The 2-methylcyclohexyl ester group adds steric bulk beyond what cyclosarin presents, pushing the limits of wild-type OPAA’s substrate tolerance. In terms of environmental persistence, EA 1356 sits at the more persistent end of the G-agent spectrum. In terms of decontamination difficulty, it exceeds both sarin and cyclosarin under enzymatic treatment conditions—which is precisely why it became the target of the 2018 engineering effort.
The relationship between these three agents illustrates a recurring theme in organophosphate chemistry: small structural changes can produce disproportionately large differences in biological and chemical behavior.
What EA-1356 Research Tells Us About Modern Chemical Defense
The EA-1356 story is ultimately a story about the intersection of chemistry, molecular biology, and defense policy. A compound synthesized during the Cold War, largely forgotten by the broader public, became the subject of cutting-edge protein engineering work decades later—producing intellectual property with potential applications far beyond its original context.
Engineered OPAA variants with improved activity against EA 1356 could, in principle, anchor next-generation decontamination formulations effective across a broader spectrum of G-agents. The biotechnology toolkit used to engineer those variants—directed evolution, rational mutagenesis, high-throughput screening—is the same toolkit driving advances across pharmaceuticals, agriculture, and industrial biotechnology. In this sense, EA-1356 decontamination research is not isolated from mainstream science; it runs parallel to it.
For researchers, policymakers, and anyone tracking the intersection of emerging technology and national security, EA 1356 is a useful case study. It demonstrates that chemical defense is not a static field—that new scientific methods continuously reshape our ability to address old threats, and that the most obscure corners of the threat landscape often drive the most technically sophisticated countermeasure work.
What the Future of EA-1356 Decontamination Research Looks Like
The 2018 OPAA patent was not an endpoint. Protein engineering techniques have continued to advance, and computational methods—including AI-driven protein structure prediction tools such as AlphaFold—are now capable of accelerating the identification of enzyme variants with improved substrate specificity. Future OPAA engineering efforts targeting EA 1356 and related compounds will almost certainly incorporate these computational tools, potentially compressing research timelines from years to months.
Simultaneously, international chemical defense organizations continue to expand their understanding of lesser-known agents to ensure that detection technologies, medical countermeasures, and decontamination protocols keep pace with the full spectrum of potential threats. EA-1356 remains on that spectrum.
EA-1356: A Small Molecule With an Outsized Scientific Legacy
EA 1356 will never be as famous as sarin. It was never deployed, never used in a confirmed attack, and remains known primarily to specialists in chemical defense and organophosphate chemistry. But its scientific legacy is real. It exposed a gap in enzymatic decontamination capability that took decades to address. It motivated protein engineering work that produced genuinely novel biotechnology. And it remains a textbook example of why broad-spectrum chemical defense capability—covering not just the most famous agents but the full structural family—matters in practice.
The U.S. Army’s 2018 patent is, in many ways, the most fitting conclusion to the EA-1356 story so far: a Cold War-era chemical agent problem solved by 21st-century biotechnology tools. That kind of temporal bridge between old threats and new science is increasingly common across defense research—and it underscores why sustained investment in basic chemical and biological research, even on obscure compounds, continues to pay dividends.
Frequently Asked Questions About EA-1356
What is EA-1356 and why is it significant?
EA-1356 (also written as EA 1356) is an organophosphate nerve agent developed and tested at Edgewood Arsenal, Maryland. Its chemical name is 2-methylcyclohexyl methylphosphonofluoridate, and it is also known as methyl cyclosarin. Its significance lies in its unusual resistance to enzymatic decontamination, which made it a long-standing challenge for chemical defense researchers and ultimately prompted a U.S. Army protein engineering program that yielded a patented breakthrough in 2018.
What are the chemical properties of EA-1356?
EA 1356 has the molecular formula C₈H₁₆FO₂P and a molar mass of 194.186 g/mol. Its CAS number is 85473-32-1. It belongs to the G-series of organophosphonate nerve agents and is structurally related to sarin and cyclosarin, differing primarily in the presence of a 2-methylcyclohexyl ester group in place of the isopropyl or cyclohexyl groups found in those agents.
How does EA-1356 affect the human body?
EA-1356 inhibits acetylcholinesterase (AChE), the enzyme responsible for terminating nerve signal transmission. By blocking AChE, EA 1356 causes uncontrolled accumulation of acetylcholine at nerve junctions, leading to excessive glandular secretions, bronchoconstriction, muscle paralysis, seizures, and—at lethal doses—respiratory failure. This mechanism is shared by all G-series nerve agents.
Why is EA-1356 harder to decontaminate than sarin or cyclosarin?
The methylcyclohexyl ester group in EA 1356 is sterically bulkier than the ester groups found in sarin (isopropyl) or cyclosarin (cyclohexyl). This additional steric bulk reduces the ability of naturally occurring organophosphorus acid anhydrolase (OPAA) to efficiently bind and hydrolyze the molecule, resulting in significantly slower enzymatic decontamination compared to other G-agents.
What did the 2018 U.S. Army patent achieve in relation to EA-1356?
U.S. Patent 10,124,043, filed in 2018, covers engineered mutations of the OPAA enzyme designed to improve catalytic efficiency against EA 1356 and related compounds. The engineered OPAA variants demonstrated approximately four times greater catalytic efficiency against EA-1356 compared to the wild-type enzyme, representing a meaningful advance in chemical defense decontamination capability.
Is EA-1356 banned under international law?
Yes. EA 1356 is classified as a Schedule 1 substance under the Chemical Weapons Convention (CWC), which prohibits its development, production, and stockpiling except in small quantities for protective research or medical countermeasure development. All Schedule 1 quantities must be declared to the Organisation for the Prohibition of Chemical Weapons (OPCW).
How is EA-1356 related to cyclosarin and sarin?
EA-1356 is structurally derived from cyclosarin (GF), which is itself a structural variant of sarin (GB). All three are G-series organophosphonate nerve agents that inhibit acetylcholinesterase. EA 1356 differs from cyclosarin by the addition of a methyl group on the cyclohexyl ring, producing greater steric bulk and making the compound more resistant to enzymatic hydrolysis than either sarin or cyclosarin.
Where was EA-1356 developed and tested?
EA 1356 was developed and tested at Edgewood Arsenal, the U.S. Army facility in Maryland that served as the primary center for chemical and biological warfare research throughout the 20th century. The “EA” prefix in EA-1356 is the Edgewood Arsenal designation prefix applied to compounds under evaluation at the facility.
